A Systematic Review of Substance Use (Disorder) in Individuals with Mild to Borderline Intellectual Disability

Neomi Van Duijvenbode, Joanne E.L. Vandernagel

Research output: Contribution to journalReview articleAcademicpeer-review

10 Downloads (Pure)

Abstract

Although the attention for substance use (SU) and SU disorders (SUD) among individuals with mild to borderline intellectual disability (MBID) has been growing exponentially, this form of dual diagnosis has largely been ignored by addiction medicine. In this article, we systematically review the research between January 2000 and June 2018 on the prevalence, assessment, and treatment of SU(D) among children, adolescents, and adults with MBID. A total of 138 articles were included. It is concluded that individuals with MBID are likely to be at a higher risk for developing SUD compared to those without MBID. Future research should focus on the detection of MBID among patients being treated in addiction medicine, the development and implementation of systematic assessment methods of SU(D) among individuals with MBID, and the development and evaluation of prevention and treatment interventions. System integration, interdisciplinary collaboration, and the development of tailored treatment for individuals with MBID are advised to improve treatment access and outcome for those who have developed SUD.

Original languageEnglish
JournalEuropean Addiction Research
DOIs
Publication statusE-pub ahead of print/First online - 22 Jul 2019

Fingerprint

Intellectual Disability
Substance-Related Disorders
disability
addiction
Medicine
Disability Evaluation
medicine
Dual (Psychiatry) Diagnosis
Systems Integration
Therapeutics
adolescent
evaluation
Research

Cite this

@article{6e52809d0b4b46fc941588805c5918e5,
title = "A Systematic Review of Substance Use (Disorder) in Individuals with Mild to Borderline Intellectual Disability",
abstract = "Although the attention for substance use (SU) and SU disorders (SUD) among individuals with mild to borderline intellectual disability (MBID) has been growing exponentially, this form of dual diagnosis has largely been ignored by addiction medicine. In this article, we systematically review the research between January 2000 and June 2018 on the prevalence, assessment, and treatment of SU(D) among children, adolescents, and adults with MBID. A total of 138 articles were included. It is concluded that individuals with MBID are likely to be at a higher risk for developing SUD compared to those without MBID. Future research should focus on the detection of MBID among patients being treated in addiction medicine, the development and implementation of systematic assessment methods of SU(D) among individuals with MBID, and the development and evaluation of prevention and treatment interventions. System integration, interdisciplinary collaboration, and the development of tailored treatment for individuals with MBID are advised to improve treatment access and outcome for those who have developed SUD.",
author = "{Van Duijvenbode}, Neomi and Vandernagel, {Joanne E.L.}",
year = "2019",
month = "7",
day = "22",
doi = "10.1159/000501679",
language = "English",
journal = "European Addiction Research",
issn = "1022-6877",
publisher = "Karger",

}

A Systematic Review of Substance Use (Disorder) in Individuals with Mild to Borderline Intellectual Disability. / Van Duijvenbode, Neomi; Vandernagel, Joanne E.L.

In: European Addiction Research, 22.07.2019.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - A Systematic Review of Substance Use (Disorder) in Individuals with Mild to Borderline Intellectual Disability

AU - Van Duijvenbode, Neomi

AU - Vandernagel, Joanne E.L.

PY - 2019/7/22

Y1 - 2019/7/22

N2 - Although the attention for substance use (SU) and SU disorders (SUD) among individuals with mild to borderline intellectual disability (MBID) has been growing exponentially, this form of dual diagnosis has largely been ignored by addiction medicine. In this article, we systematically review the research between January 2000 and June 2018 on the prevalence, assessment, and treatment of SU(D) among children, adolescents, and adults with MBID. A total of 138 articles were included. It is concluded that individuals with MBID are likely to be at a higher risk for developing SUD compared to those without MBID. Future research should focus on the detection of MBID among patients being treated in addiction medicine, the development and implementation of systematic assessment methods of SU(D) among individuals with MBID, and the development and evaluation of prevention and treatment interventions. System integration, interdisciplinary collaboration, and the development of tailored treatment for individuals with MBID are advised to improve treatment access and outcome for those who have developed SUD.

AB - Although the attention for substance use (SU) and SU disorders (SUD) among individuals with mild to borderline intellectual disability (MBID) has been growing exponentially, this form of dual diagnosis has largely been ignored by addiction medicine. In this article, we systematically review the research between January 2000 and June 2018 on the prevalence, assessment, and treatment of SU(D) among children, adolescents, and adults with MBID. A total of 138 articles were included. It is concluded that individuals with MBID are likely to be at a higher risk for developing SUD compared to those without MBID. Future research should focus on the detection of MBID among patients being treated in addiction medicine, the development and implementation of systematic assessment methods of SU(D) among individuals with MBID, and the development and evaluation of prevention and treatment interventions. System integration, interdisciplinary collaboration, and the development of tailored treatment for individuals with MBID are advised to improve treatment access and outcome for those who have developed SUD.

U2 - 10.1159/000501679

DO - 10.1159/000501679

M3 - Review article

JO - European Addiction Research

JF - European Addiction Research

SN - 1022-6877

ER -